The company recently announced intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies with the strategic opportunities of each company. The company's pipeline includes rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease; and ANB101, a BDCA2 modulator, in a Phase 1a trial.
Cyborg Score Rationale
AnaptysBio demonstrates strong fundamentals with $300M+ anticipated year-end cash position, a compelling royalty stream from Jemperli sales ($785M YTD 2025), and multiple Phase 2 clinical assets with differentiated mechanisms targeting immune checkpoints. However, clinical-stage risk remains material, and the planned company separation adds execution complexity.
Top Insights
Jemperli (dostarlimab) becoming blockbuster with >$2.7B peak sales guidance; Anaptys entitled to ~$390M annualized royalties at peak
Strategic separation by end-2026 will create pure-play royalty company and focused biopharma developer, improving capital allocation flexibility
Lead program rosnilimab (T cell depletion) completed Phase 2b in rheumatoid arthritis; now progressing to Phase 2 in ulcerative colitis
Multiple first-in-class assets with differentiated mechanisms (checkpoint agonists, CD122 antagonist, BDCA2 modulator) targeting large autoimmune markets
Named Competitors
Keytruda (pembrolizumab) — PD-1 inhibitor in dMMR endometrial cancer and other oncology indications
Dupilumab — IL-4R antagonist for atopic dermatitis and other inflammatory conditions
Baricitinib/Olumiant — JAK inhibitor for rheumatoid arthritis and inflammatory conditions
Tildrakizumab — IL-23 antagonist for psoriasis
Recent Developments
(November 2025) $100 million stock repurchase authorization announced; $300M+ anticipated cash position by year-end 2025
(October 2025) Q3 2025 results showed Jemperli YTD sales of $785M with >16% USD quarterly growth; anticipated $75M milestone in Q4 2025
(January 2026) CEO Daniel Faga presented at J.P. Morgan Healthcare Conference reinforcing separation strategy and pipeline progress
(November 2025) Announced formal intent to separate biopharma operations from royalty assets by year-end 2026
Open the full interactive AnaptysBio, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.